There is an enormous effort driving innovation in anti-cancer medicines, yet surprisingly little is known about how different drugs are being used in clinical practice today.

The Collaboration for Oncology Data in Europe (CODE) aims to expand our knowledge of anti-cancer medicines use by supporting the development of a dedicated Oncology Data Network. The data collated will enable the oncology community to derive greater value from anti-cancer medicines for patients.

The technology platform that underpins the Oncology Data Network is custom designed with the security and scale needed for the objectives of CODE. It has been conceived to be able to aggregate data for all forms of cancer, in all patients at Europe’s cancer treatment centres, in near real-time, on how anti-cancer medicines are being used in today’s clinical practice, in which patient groups and in which combinations and sequences.

The aim is to collaborate with 200 cancer treatment centres in seven European countries in the first three years, scaling to an estimated 2,000 treatment centres across Europe over 10 years.

CODE was formally launched at the 2017 annual European Society for Medical Oncology (ESMO) Congress in Madrid. Please click here for a report of the event.

CODE’s vision is to enable the oncology community to keep pace with innovation and derive greater value from anti-cancer treatments for patients by establishing the first comprehensive long-term Oncology Data Network across Europe.

CODE’s aim is to ensure comprehensive, up-to-date and validated data on how anti-cancer medicines are actually used in clinical practice across Europe are collated, in order to provide the oncology community with near real-time information around anti-cancer medicines use.

Integrity

Supporting the creation of an Oncology Data Network which will incorporate the guidance and direction from cancer experts and respects high standards of patient privacy and data protection

Inclusive

Working in partnership with healthcare professionals, industry, governments and patient groups to ensure that CODE is relevant and understands the needs of the broader oncology community

Ambition

Delivering the first large-scale, Oncology Data Network across Europe, led by IQVIA (formerly QuintilesIMS) and supported initially by the Founding Members, then by a broadening collaboration of stakeholders

Commitment

Dedicated to help optimise cancer care and treatment access for patients through the long-term provision of data on anti-cancer medicines use to the European oncology community

Supportive

Encouraging treatment centres, clinicians and hospital teams to participate, by simplifying to the greatest extent possible entry to and participation in the Oncology Data Network

Collaboration

Partnering with as many treatment centres in Europe as wish to join. The value of the network grows for all with increased participation